Search - tctmd.com

Displaying 1 - 20 of 49

Sort: Relevancy | Date

TAVI, SAVR Rates Roughly Equal for Patients Younger Than 65 in New England

News Conference News ACC 2024

TAVI, SAVR Rates Roughly Equal for Patients Younger Than 65 in New England

Yael L. Maxwell

April 05, 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

News Conference News ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Michael O'Riordan

March 27, 2024

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

News Conference News ACC 2023

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

Yael L. Maxwell

March 09, 2023

Leaks After LAA Occlusion Tied to Uptick in Thromboembolic Events

News Conference News ACC 2022

Leaks After LAA Occlusion Tied to Uptick in Thromboembolic Events

April 04, 2022

Low 1-Year Stroke Risk After Commercial Watchman Use

News Conference News ACC 2021

Low 1-Year Stroke Risk After Commercial Watchman Use

May 15, 2021

High- and Low-Dose Aspirin Equivalent in ASCVD: ADAPTABLE

News Conference News ACC 2021

High- and Low-Dose Aspirin Equivalent in ASCVD: ADAPTABLE

Michael O'Riordan

May 15, 2021

Poorer Neighborhoods Pose Risks for Black Patients After Acute MI

News Conference News ACC 2021

Poorer Neighborhoods Pose Risks for Black Patients After Acute MI

May 05, 2021

Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds

News Conference News ACC 2020

Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds

March 25, 2020

Lower Risk of Death With Conscious Sedation in TAVR: TVT Registry

News Conference News ACC 2020

Lower Risk of Death With Conscious Sedation in TAVR: TVT Registry

Michael O'Riordan

March 19, 2020

Under 40, or 10 Years Older: MI Survivors Face Similar Long-term Mortality Risks

News Conference News ACC 2019

Under 40, or 10 Years Older: MI Survivors Face Similar Long-term Mortality Risks

March 07, 2019

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

Urgent/Emergent TAVR: Risky but Rewarding, TVT Registry Data Hint

News Conference News ACC 2018

Urgent/Emergent TAVR: Risky but Rewarding, TVT Registry Data Hint

March 19, 2018

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

News Conference News ACC 2018

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

Michael O'Riordan

March 14, 2018

Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues

News Conference News ACC 2018

Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues

Michael O'Riordan

March 11, 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

March 05, 2018

MitraClip Commercial Experience at 1 Year Sheds Light on Progress and Lingering Concerns

News Conference News ACC 2017

MitraClip Commercial Experience at 1 Year Sheds Light on Progress and Lingering Concerns

March 27, 2017

My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time

News Conference News ACC 2017

My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time

March 23, 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

News Conference News ACC 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Yael L. Maxwell

March 23, 2017

Prioritizing Impella Support May Boost Cardiogenic Shock Survival, Pilot Study Suggests

News Conference News ACC 2017

Prioritizing Impella Support May Boost Cardiogenic Shock Survival, Pilot Study Suggests

March 22, 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.